Clinical Research Transformation In Riyadh: 2026 Outlook Conference Brings Global Expertise

The "Clinical Research Transformation: Future Outlook 2026" conference opened in Riyadh, organised by King Faisal Specialist Hospital and Research Centre (KFSHRC). The event aimed to advance the Kingdom’s clinical research ecosystem and link scientific studies with daily clinical practice, helping improve specialised therapies and medical innovation efficiency.

The conference formed part of a wider shift in Saudi Arabia’s health research sector, which has seen fast progress in biotechnology and medical innovation. This development aligned with Saudi Vision 2030 and the National Biotechnology Strategy 2040, supporting a healthcare model based on knowledge and innovation.

According to KFSHRC, the conference brought together leaders and specialists in clinical research, biotechnology and healthcare innovation from North America, Europe and Saudi Arabia. Participants discussed how to strengthen national capabilities, while also connecting local efforts with global trends and strategic health objectives.

Sessions at the event examined regulatory, technical and ethical issues linked to advancing clinical research. Speakers reviewed national and international models for building integrated and sustainable research ecosystems. They also discussed how digital technologies and artificial intelligence could improve research efficiency and support regulatory and oversight processes.

The conference also highlighted KFSHRC’s recent international rankings and brand position within healthcare. These indicators reflected the institution’s growing role in clinical research, biotechnology and medical innovation, both in Saudi Arabia and abroad, during the current phase of health system development.

{TABLE_1}

The event served as a professional platform for exchanging expertise and building partnerships among researchers, organisations and relevant authorities. By supporting dialogue on policy, technology and ethics, the conference contributed to strengthening the Kingdom’s clinical research ecosystem and its integration with long-term national health and biotechnology strategies.

With inputs from SPA